|Bid||323.80 x 900|
|Ask||325.00 x 1100|
|Day's range||320.01 - 327.05|
|52-week range||220.20 - 330.85|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||49.50|
|Earnings date||25 Apr 2022 - 29 Apr 2022|
|Forward dividend & yield||3.92 (1.34%)|
|Ex-dividend date||13 May 2022|
|1y target est||304.28|
Shares of drugmaker Eli Lilly (NYSE: LLY) have suffered the same occasional tumble that its pharma peers and the broad market have taken this year. Whereas the Dow Jones Industrial Average is down 13% year to date and the Dow Jones Pharmaceutical Index is just slightly better than breakeven, Lilly shares are up more than 18% since the end of 2021. Much credit goes to Eli Lilly's COVID-19 treatment combination of bamlanivimab and etesevimab although its diabetes treatment Trulicity has been a heavy hitter as well.
Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale are part of Zacks top Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY), and The Home Depot, Inc. (HD).